Operating Performance - The total revenue for the first quarter of 2025 was 810 million yuan, a year-on-year decrease of 4.25% [1] - The net profit attributable to the parent company was 22.982 million yuan, down 49.07% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 20.4398 million yuan, a decline of 50.66% year-on-year [1] Profitability - The gross profit margin was 19.36%, a decrease of 10.57% year-on-year [2] - The net profit margin was 3.11%, down 48.55% year-on-year [2] - Earnings per share were 0.04 yuan, a decrease of 57.95% year-on-year [2] Cost Control - Total selling, administrative, and financial expenses amounted to 110 million yuan, accounting for 13.56% of revenue, an increase of 20.88% year-on-year [3] Asset and Liability Situation - Cash and cash equivalents were 1.323 billion yuan, a decrease of 27.19% year-on-year [4] - Accounts receivable were 571 million yuan, an increase of 15.61% year-on-year [4] - Interest-bearing liabilities surged to 153 million yuan, a dramatic increase of 46346.96% year-on-year [4] Cash Flow - Operating cash flow per share was -0.09 yuan, an improvement of 42.56% year-on-year, but still negative, indicating a need for further optimization in cash flow from operations [5] Business Model and Financing Dividends - The company's performance is primarily driven by R&D, marketing, and equity financing [6] - Since its listing, the total financing amount has reached 1.422 billion yuan, with total dividends amounting to 1.888 billion yuan, resulting in a dividend-to-financing ratio of 1.33, reflecting a positive attitude towards shareholder returns [6] Summary - Overall, the financial performance of the company in the first quarter of 2025 was unsatisfactory, with a significant decline in net profit, and notable increases in accounts receivable and interest-bearing liabilities, necessitating close attention to subsequent operational strategy adjustments and financial condition improvement measures [7]

证券代码：000919 证券简称：金陵药业 公告编号：2025-033 截至 2025 年 3 月 31 日，公司及子公司与多家银行签署了购买理 财产品协议（包括结构性存款），现将公司及子公司使用闲置资金购 买理财产品情况公告如下： 公司及子公司与以下银行不存在关联关系，所购买的理财产品均 为低风险理财产品，未到期的理财产品未发现异常情况。 | 序 | 购买主体 | 发行主体 | 产品名称 | 购买金额 | 购买日期 | 到期日期 | 是否 | 本金 | 理财收益 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | （万元） | | | 赎回 | （万元） | （万元） | | 1 | 金陵药业股份有 | 浙商银行河西支行 | 结构性存款 | 500 | 2025.01.24 | 2025.02.07 | 是 | 500 | 0.33 | | | 限公司 | | | | | | | | | | 2 | 金陵药业股份有 | 中信银行月牙湖支 | 结构性存款 | 2,000 | 2025.02.01 | 2025. ...

报告开篇 1 关于本报告 1 董事长致辞 3 关于金陵药业 4 公司治理与 稳健经营 | 党建引领 | 13 | | --- | --- | | 公司治理架构 | 15 | | 商业道德与反腐败 | 17 | | 合规经营与风险控制 | 18 | | 数据安全与隐私保护 | 19 | 产品责任与 医患服务 | 持续创新 | 32 | | --- | --- | | 注重医药与服务可及性 | 34 | | 专注服务产品质量 | 36 | | 深化客户服务 | 39 | 员工雇佣与 发展 | 员工发展 | 47 | | --- | --- | | 健康与安全 | 54 | 供应链与 社会责任 | 负责任供应链 | 42 | | --- | --- | | 社会公益与乡村振兴 | 43 | 报告附录 | 量化数据绩效 | 58 | | --- | --- | | 报告索引表 | 59 | 报告开篇 董事长致辞 可持续发展（ESG）管理 公司治理与稳健经营 气候行动与绿色共赢 产品责任与医患服务 供应链与社会责任 员工雇佣与发展 报告附录 可持续发展 （ESG）管理 报告开篇 | ESG 治理体系 | 9 | | - ...

证券代码：000919 证券简称：金陵药业 公告编号：2025-031 金陵药业股份有限公司 关于同一控制下企业合并追溯调整财务数据的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 金陵药业股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第九届董事会第十七次会议，审议通过了《关于同一控制下企 业合并追溯调整财务数据的议案》。具体情况如下： 一、同一控制下企业合并的基本情况及追溯调整财务报表数据的 原因 2024 年 10 月 18 日，公司与南京新工投资集团有限责任公司（以 下简称"新工集团"）、南京新工新兴产业投资管理有限公司（以下 简称"新工新兴"）、南京紫金资产管理有限公司（以下简称"紫金 资管"）签署《基金份额转让协议》，以现金方式受让新工集团持有 的南京新工医疗产业投资基金合伙企业（有限合伙）（以下简称"基 金"）28.46%出资份额和紫金资管持有的基金 16.67%出资份额。公 司原持有基金份额的 33.33%，上述基金份额转让完成后，公司合计 持有基金 78.46%的份额。后续公司与新工集团、新工新兴将基金持 有的南京 ...

一、监事会会议召开情况 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：000919 证券简称：金陵药业 公告编号：2025-030 金陵药业股份有限公司 第九届监事会第十七次会议决议公告 二、监事会会议审议情况 1、审议通过了《关于同一控制下企业合并追溯调整财务数据的 议案》。 监事会认为：公司本次追溯调整事项符合《企业会计准则》等的 相关规定，追溯调整后的财务报表能够客观公允地反映公司财务状况。 本次追溯调整事项的决策程序符合有关法律、法规和《公司章程》的 规定，不存在损害公司及全体股东利益的情形。 表决结果：5 票同意，0 票反对，0 票弃权。 1、金陵药业股份有限公司（以下简称"公司"）第九届监事会第 十七次会议通知于 2025 年 4 月 15 日以专人送达、邮寄、电子邮件等 方式发出。 2、本次会议于 2025 年 4 月 25 日以通讯会议的方式召开。 3、会议应参与表决监事 5 名，实际参与表决监事 5 名，收到有 效表决票 5 张。 4、本次监事会会议的召开符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 监事会 ...

金陵药业股份有限公司监事会 关于第九届监事会第十七次会议相关事项的审核意见 监事会认为：公司本次追溯调整事项符合《企业会计准则》等的 相关规定，追溯调整后的财务报表能够客观公允地反映公司财务状况 。本次追溯调整事项的决策程序符合有关法律、法规和《公司章程》 的规定，不存在损害公司及全体股东利益的情形。 二、关于公司2025年第一季度报告的审核意见 监事会认为董事会编制和审议公司2025年第一季度报告的程序 符合法律、行政法规及中国证监会的规定，报告内容真实、准确、完 整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述 或者重大遗漏。 根据《中华人民共和国公司法》《深圳证券交易所股票上市规则 》《上市公司自律监管指引第1号——主板上市公司规范运作》等有 关法律法规、规范性文件及《公司章程》的规定，金陵药业股份有限 公司（以下简称"公司"）监事会对公司第九届监事会第十七次会议 审议的相关事项进行了认真审核，发表审核意见如下： 一、关于同一控制下企业合并追溯调整财务数据的审核意见 ...

证券代码：000919 证券简称：金陵药业 公告编号：2025-029 金陵药业股份有限公司 第九届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、金陵药业股份有限公司（以下简称"公司"）第九届董事会 第十七次会议通知于 2025 年 4 月 15 日以专人送达、邮寄、电子邮件 等方式发出。 2、本次会议于 2025 年 4 月 25 日以通讯会议的方式召开。 3、会议应参与表决董事 9 名，实际参与表决董事 9 名，收到有 效表决票 9 张。 4、本次董事会会议的召开符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 二、董事会会议审议情况 1、审议通过了《关于同一控制下企业合并追溯调整财务数据的 议案》。 董事会认为：公司本次追溯调整事项符合《企业会计准则》等的 相关规定，追溯调整后的财务报表客观、公允地反映了公司实际经营 状况，不存在损害公司及全体股东利益的情形。同意本次追溯调整事 项。 表决结果：9 票同意，0 票反对，0 票弃权。 本议案已经公司董事会审计委员会审议通过。具体内 ...

Financial Performance - The company's revenue for Q1 2025 was ¥810,013,922.67, a decrease of 4.25% compared to ¥845,969,077.98 in the same period last year[5] - Net profit attributable to shareholders decreased by 49.07% to ¥22,981,989.14 from ¥45,124,738.44 year-on-year[5] - The basic earnings per share fell by 57.95% to ¥0.0370 from ¥0.0880 in the previous year[5] - Total operating revenue for the current period was ¥810,013,922.67, a decrease of 4.2% from ¥845,969,077.98 in the previous period[16] - Net profit for the current period was ¥25,174,905.26, down 50.8% from ¥51,100,581.72 in the previous period[17] - Total comprehensive income for the period was CNY 25,174,905.26, compared to CNY 51,100,581.72 in the previous period[18] - Net income attributable to the parent company was CNY 22,981,989.14, down from CNY 45,124,738.44 year-over-year[18] - Basic and diluted earnings per share were both CNY 0.0370, compared to CNY 0.0880 in the previous period[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,058,368,649.99, a decrease of 0.50% from ¥6,088,855,025.59 at the end of the previous year[5] - Total liabilities decreased to ¥1,184,699,361.12 from ¥1,240,278,401.94, a reduction of 4.5%[15] - The company's total equity attributable to shareholders increased by 0.60% to ¥3,814,019,370.53 from ¥3,791,090,837.42 at the end of the previous year[5] - The company's total equity increased to ¥4,873,669,288.87 from ¥4,848,576,623.65, an increase of 0.5%[15] Cash Flow - Cash flow from operating activities showed a net outflow of ¥57,763,324.07, an improvement of 29.91% compared to the outflow of ¥82,417,561.00 in the previous year[5] - Cash inflows from operating activities totaled CNY 748,869,645.07, slightly down from CNY 752,762,424.77[19] - Net cash outflow from operating activities was CNY -57,763,324.07, an improvement from CNY -82,417,561.00 in the previous period[19] - Cash inflows from investing activities were CNY 421,246,729.65, compared to CNY 313,928,236.83 in the previous period[20] - Net cash outflow from investing activities was CNY -418,189,065.94, worsening from CNY -60,856,143.85 year-over-year[20] - Cash and cash equivalents at the end of the period were CNY 1,104,500,475.08, down from CNY 1,937,777,334.28[20] - The company did not receive any cash from financing activities, compared to CNY 742,632,289.33 in the previous period[20] Expenses - The company's sales expenses surged by 223.21% to ¥22,006,480.98, attributed to increased marketing activities[8] - Total operating costs increased to ¥788,644,161.76, up from ¥782,749,272.77, reflecting a rise of 0.1%[16] - Research and development expenses were ¥21,182,611.02, slightly up from ¥20,776,182.16, indicating a focus on innovation[16] - The company experienced a 67.28% reduction in income tax expenses, amounting to ¥5,006,368.30 compared to ¥15,299,165.89 in the previous year[8] Investments - The company reported a significant increase in investment income, which rose by 151.44% to ¥9,392,399.03 from ¥3,735,392.36 year-on-year[8] - The company reported an investment income of ¥9,392,399.03, significantly higher than ¥3,735,392.36 in the previous period[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 35,998[10] - The largest shareholder, Nanjing New Industry Investment Group, holds 41.59% of shares, totaling 259,390,380 shares[10] - The company has not reported any changes in the top 10 shareholders due to securities lending[11] Future Plans and Legal Matters - The company plans to liquidate and deregister the Nanjing New Industry Medical Investment Fund Partnership[11] - The company has received a court ruling dismissing a retrial application related to a civil case[11] - The company is expected to disclose related party transactions for the year 2025[11] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[16] Other Information - Cash and cash equivalents decreased from ¥1,770,945,293.91 to ¥1,323,186,708.62, a decline of approximately 25.2%[13] - Trading financial assets increased from ¥706,046,500.54 to ¥1,042,055,857.89, an increase of approximately 47.6%[13] - Accounts receivable rose from ¥438,924,723.85 to ¥570,542,556.39, an increase of approximately 30%[13] - Inventory decreased from ¥271,624,277.17 to ¥250,837,970.04, a decline of approximately 7.6%[13] - The company’s first quarter report was not audited[21]

Group 1: Financial Performance - The company repurchased 5.35 million restricted stock units using 18.76 million CNY of its own funds in 2024 [2] - The net profit for 2024 significantly declined due to three main factors: goodwill impairment, increased R&D expenses by 52.64%, and decreased profits in the healthcare sector due to policy reforms [2][3] - The company reported a goodwill increase of 121,391,986.07 CNY from acquiring 51% of Meishan Hospital, which negatively impacted the profit by 77,018,945.37 CNY due to retrospective adjustments [2][4] Group 2: Future Growth Strategies - The company plans to enhance profitability by focusing on three areas: accelerating new product R&D, increasing sales of existing high-margin products, and improving cost management [2] - The company has established a 355-acre traditional Chinese medicine demonstration base to promote cultivation and quality control [3] - The company is investing in R&D for various therapeutic areas, including anti-anemia, gynecology, nephrology, and medical devices, to improve innovation and market competitiveness [4] Group 3: Shareholder Engagement - As of April 1, 2025, the number of shareholders is 35,487 [3] - The company has distributed over 1.88 billion CNY in dividends since its listing, with annual dividends exceeding 50% of the net profit in the last three years [3] - The company plans to disclose its Q1 2025 report on April 28, 2025 [4]

中信证券股份有限公司 关于金陵药业股份有限公司 2024 年度保荐工作报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：金陵药业 | | --- | --- | | 保荐代表人姓名：屠晶晶 | 联系电话：021-20262237 | | 保荐代表人姓名：王昭辉 | 联系电话：021-20262237 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度） | | | （2）公司是否有效执行相关规章制度 | 是，根据《金陵药业股份有限公司2024年度内 部控制评价报告》、《金陵药业股份有限公司 | | | 内部控制审计报告》，发行人有效执行了相关 | | | 规章制度。 | | 3.募集资金监 ...